Section 21: how it works and where it is recognized
A cross-border regulatory framework for supplying an unregistered or off-label medicine to a specific patient, on the order of a treating physician, under a defined permit issued by the destination-country medicines regulator.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
What Section 21 is
Origin and authorising body. United Kingdom, under Section 21 of the Human Tissue Act 2004. The authorising body for each individual case is the Human Tissue Authority (HTA), with the MHRA for tissue-derived medicinal products and EMA at the European level for advanced therapy medicinal products, acting under that jurisdiction's pharmacy or medicines legislation.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Legal basis. Section 21 of the Human Tissue Act 2004 governs the licensing of activities involving relevant material from human bodies. The HTA licenses establishments to store and use human tissue for scheduled purposes including transplantation, research, and (where applicable) the manufacture of tissue-derived medicinal products. Tissue-derived therapies that meet the definition of an advanced therapy medicinal product also fall under EMA and MHRA oversight under Regulation (EC) No 1394/2007.
Section 21 frameworks govern the supply and use of human-tissue-derived therapies including allogeneic cell therapies, certain regenerative medicine products, and specialty biologics derived from human cells or tissue. The framework intersects with the advanced therapy medicinal product (ATMP) regulatory architecture and with Hospital Exemption rules for non-routine ATMPs. Cross-border access to Section 21 therapies is operationally complex because the source-country and destination-country tissue regulations must both be satisfied.
Section 21 itself is the licensing provision; the operational frameworks for individual-patient supply of tissue-derived therapies typically use the broader specials, named-patient, or hospital-exemption mechanisms layered on top of Section 21 establishment licensing.
This page consolidates Reserve Meds's operational view of the Section 21 (UK Human Tissue Act) framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Section 21 (UK Human Tissue Act)-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.
Reserved for you.
Who can use Section 21
Section 21 framework applies to licensed establishments handling human tissue in the UK. Patient access to tissue-derived therapies operates through the prescriber and the licensed dispensing establishment. Cross-border patients require parallel destination-country tissue and pharmacy authorisations.
In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.
Drug categories typically covered under Section 21
Allogeneic cell therapies, certain gene-modified cell therapies, regenerative medicine products derived from human tissue, and specialty biologics.
The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Section 21 (UK Human Tissue Act) import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.
Country compatibility
The table below summarises how the Section 21 (UK Human Tissue Act) framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Section 21 (UK Human Tissue Act) dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Section 21 (UK Human Tissue Act) clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.
| Country | Local pathway equivalent | Accepts Section 21 (UK Human Tissue Act) dossiers? | Typical timeline | Local regulator |
|---|---|---|---|---|
| Bahrain | NHRA Compassionate / Special Import Permit | Indirect (reference precedent only) | 5 to 15 business days | NHRA |
| Egypt | EDA Single-Patient Import (Decree 425) | Indirect (reference precedent only) | 10 to 25 business days | EDA |
| India | Rule 36 personal-use import (D&C Rules 1945) | Indirect (reference precedent only) | 7 to 21 business days | CDSCO |
| Jordan | JFDA Compassionate / Special Use Import | Indirect (reference precedent only) | 10 to 20 business days | JFDA |
| Kuwait | MoH Unregistered Medicine Import Permit | Indirect (reference precedent only) | 10 to 20 business days | KDFC (MoH) |
| Lebanon | MoPH Special Import for Named Patient | Indirect (reference precedent only) | 10 to 25 business days | MoPH |
| Oman | MoH Compassionate / Named-Patient Import | Indirect (reference precedent only) | 10 to 20 business days | MoH-DGPADC |
| Qatar | MoPH Single-Patient Unregistered Drug Import | Indirect (reference precedent only) | 10 to 20 business days | MoPH-DPA |
| Saudi Arabia | SFDA Personal Importation Permit | Indirect (reference precedent only) | 10 to 25 business days | SFDA |
| United Arab Emirates | EDE Unregistered Medicine Import Permit | Indirect (reference precedent only) | 5 to 15 business days | EDE |
Notes. "Indirect" means the destination regulator does not directly accept Section 21 (UK Human Tissue Act) authorisation as the legal basis for import but does recognise a Section 21 (UK Human Tissue Act) authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).
Documentation required
A Section 21 application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).
- HTA establishment licence at the dispensing site.
- Treating physician's prescription with clinical justification.
- Patient informed consent (including for any human-tissue-derived therapy).
- Manufacturer or source-establishment chain-of-custody documentation.
- For ATMPs: MHRA or EMA authorisation under the relevant framework.
- For cross-border: destination-country tissue regulator authorisation.
Typical timeline
Section 21 supply timelines depend on the specific therapy and on the underlying authorisation framework (named-patient, hospital exemption, or ATMP commercial supply). Routine cases: 4 to 8 weeks. First-import or first-use cases: 8 to 16 weeks.
Costs and reimbursement
Tissue-derived therapies are typically high-cost (often six-figure per-course in the UK). NHS reimbursement is determined case by case; private patients pay the manufacturer's stated price. Cross-border patients pay the relevant per-country acquisition cost plus logistics, customs, dispensing, and coordinator fees.
Where Reserve Meds fits in
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Section 21 (UK Human Tissue Act) cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.
For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.
Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.
Next step
If your treating physician has identified a clinical need that fits the Section 21 (UK Human Tissue Act) framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.